DDInter1607 DDInter1070
Ritonavir is an HIV protease inhibitor that interferes with the reproductive cycle of HIV. Although it was initially developed as an independent antiviral agent, it has been shown to possess advantageous properties in combination regimens with low-dose ritonavir and other protease inhibitors. It is now more commonly used as a booster of other protease inhibitors and is available in both liquid formulations and as capsules. While ritonavir is not an active antiviral agent against hepatitis C virus (HCV) infection, it is added in combination therapies indicated for the treatment of HCV infections as a booster. Ritonavir is a potent CYP3A inhibitor that increases peak and trough plasma drug concentrations of other protease inhibitors such as and overall drug exposure. American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) guidelines recommend ritonavir-boosted combination therapies as first-line therapy for HCV Genotype 1a/b and
Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin was approved by the FDA on May 2, 2011.
Ritonavir {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Linagliptin
Ritonavir {u} (Compound) causes {v} (Side Effect) Headache
Headache {u} (Side Effect) is caused by {v} (Compound) Linagliptin
Ritonavir {u} (Compound) resembles {v} (Compound) Atazanavir
Atazanavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Linagliptin
Ritonavir {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Alogliptin
Alogliptin {u} (Compound) resembles {v} (Compound) Linagliptin
Ritonavir {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Betamethasone
Betamethasone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Linagliptin
Ritonavir {u} (Compound) causes {v} (Side Effect) Headache
Headache {u} (Side Effect) is caused by {v} (Compound) Alogliptin
Alogliptin {u} (Compound) resembles {v} (Compound) Linagliptin
Ritonavir {u} (Compound) causes {v} (Side Effect) Musculoskeletal discomfort
Musculoskeletal discomfort {u} (Side Effect) is caused by {v} (Compound) Betamethasone
Betamethasone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Linagliptin
Ritonavir {u} (Compound) resembles {v} (Compound) Atazanavir
Atazanavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alogliptin
Alogliptin {u} (Compound) resembles {v} (Compound) Linagliptin
Ritonavir {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is associated with {v} (Disease) type 2 diabetes mellitus
type 2 diabetes mellitus {u} (Disease) is treated by {v} (Compound) Linagliptin
Ritonavir {u} (Compound) causes {v} (Side Effect) Dermatitis
Dermatitis {u} (Side Effect) is caused by {v} (Compound) Amcinonide
Amcinonide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Linagliptin
Ritonavir (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Linagliptin (Compound)
Ritonavir (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Linagliptin (Compound)
Ritonavir (Compound) resembles Atazanavir (Compound) and Atazanavir may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin
Ritonavir (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Alogliptin (Compound) and Alogliptin (Compound) resembles Linagliptin (Compound)
Ritonavir (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Betamethasone (Compound) and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin
Ritonavir (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Alogliptin (Compound) and Alogliptin (Compound) resembles Linagliptin (Compound)
Ritonavir (Compound) causes Musculoskeletal discomfort (Side Effect) and Musculoskeletal discomfort (Side Effect) is caused by Betamethasone (Compound) and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin
Ritonavir (Compound) resembles Atazanavir (Compound) and Atazanavir may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin and Alogliptin (Compound) resembles Linagliptin (Compound)
Ritonavir (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is associated with type 2 diabetes mellitus (Disease) and type 2 diabetes mellitus (Disease) is treated by Linagliptin (Compound)
Ritonavir (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Amcinonide (Compound) and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Linagliptin